Local drug manufacturers have dominated the oncology market in China in recent years, but large multinational pharmaceutical companies are gaining momentum with new, targeted therapies
Plymouth Meeting, PA (Vocus) July 22, 2010
NORWALK, CT, July 22, 2010 – IMS Health, the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries, today announced the expansion of IMS Oncology Analyzer to additional cities in China. The market measurement tool enables IMS’s pharmaceutical clients to assess treatments and guide commercial decisions in that country’s fast-growing, $1.5+ billion oncology market. IMS Oncology Analyzer now covers twelve Tier 1 and Tier 2 cities in China, providing the most clinically comprehensive view of cancer care from first diagnosis forward – facilitating critical market research insights for areas such as product adoption, dosing and regimen compliance, and market sizing.
Delivering commercial and clinical insight into oncology product uptake and treatment patterns, IMS Oncology Analyzer is the only anonymized patient-level information resource in China that captures all cancer treatment modalities across all tumor types.
By the end of 2011, China is expected to become the world’s third-largest pharmaceutical market, growing more than 20 percent annually. Oncology, the largest therapeutic area globally, is among the top five therapy classes in China, where compound annual growth has exceeded 25 percent over the past five years.
“Local drug manufacturers have dominated the oncology market in China in recent years, but large multinational pharmaceutical companies are gaining momentum with new, targeted therapies,” said Steven Gavel, global director, Oncology, IMS. “The focus on cancer prevention and treatment is leading to greater access to all cancer therapies in the country, as well as improved diagnoses and treatments for an aging patient population. IMS Oncology Analyzer is an essential tool for measuring success in this rapidly expanding market.”
IMS Oncology Analyzer is an evidence-based, quantitative market research tool to measure life cycle management strategies, product performance plans, new indication opportunities and many other relevant commercial planning activities. In addition to China, the offering is available in the U.K., France, Italy, Spain, Germany, Turkey, the Netherlands, Japan, Korea and Taiwan.
Operating in more than 100 countries, IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. With more than 55 years of industry experience, IMS Health offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations, including product and portfolio management capabilities; commercial effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve productivity and the delivery of quality healthcare worldwide. Additional information is available at http://www.imshealth.com.